Development of matrix metalloproteinase inhibitors in cancer therapy Review uri icon

Overview

MeSH Major

  • Matrix Metalloproteinase Inhibitors
  • Neoplasm Proteins
  • Neoplasms
  • Protease Inhibitors

abstract

  • The matrix metalloproteinases represent an attractive target for cancer treatment, and a number of matrix metalloproteinase inhibitors are undergoing clinical trials. The results of these studies will establish whether any of these compounds are therapeutically useful. Independent of the conclusions from the first generation of studies, the field of matrix metalloproteinase inhibitors remains attractive for creative and innovative research. In the future, the development of novel, less toxic, and more effective matrix metalloproteinase inhibitors, and the combination of conventional agents with these novel anticancer agents will constitute the main focus of research efforts.

publication date

  • October 2002

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/S0889-8588(02)00044-8

PubMed ID

  • 12512389

Additional Document Info

start page

  • 1189

end page

  • 227

volume

  • 16

number

  • 5